Adding elesclomol to paclitaxel for advanced melanoma studied

Adding elesclomol to paclitaxel for advanced melanoma studied
Lactate dehydrogenase levels may be predictive of success in treating chemotherapy-naive patients with advanced melanoma with a combination of elesclomol plus paclitaxel, according to research published online Feb. 11 in the Journal of Clinical Oncology.

(HealthDay)—Lactate dehydrogenase (LDH) levels may be predictive of success in treating chemotherapy-naive patients with advanced melanoma with a combination of elesclomol plus paclitaxel, according to research published online Feb. 11 in the Journal of Clinical Oncology.

Steven J. O'Day, M.D., of the Los Angeles Skin Cancer Institute in Beverly Hills, Calif., and colleagues conducted a randomized, double-blind trial of paclitaxel 80 mg/m² alone or with elesclomol 213 mg/m² as treatment for 651 chemotherapy-naive patients with advanced melanoma.

This study was ended prematurely due to a higher number of deaths in patients treated with paclitaxel alone; therefore, its primary progression-free survival (PFS) end point was not met. The researchers found that paclitaxel-only treated patients tended to have higher LDH levels. However, subgroup analysis did find that median PFS was significantly improved in patients who received combination treatment and who had normal baseline LDH levels.

"In conclusion, the SYMMETRY study did not achieve its primary end point," the authors write. "Prespecified and exploratory analyses suggest that baseline LDH levels may predict treatment outcomes for elesclomol. Literature reports suggest that LDH may more broadly predict activity of other specific for metabolic states of ."

The study was supported by Synta Pharmaceuticals, the manufacturer of elesclomol; several authors disclosed to pharmaceutical companies, including Synta.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Study reveals new molecular target for melanoma treatment

Aug 17, 2012

A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been ...

Cetuximab, paclitaxel combo active in urothelial cancer

Aug 29, 2012

(HealthDay)—The monoclonal antibody against epidermal growth factor receptor (EGFR), cetuximab, augments the antitumor activity of paclitaxel in patients with previously treated urothelial cancer, according ...

Blood test could guide treatment for kidney cancer

Aug 13, 2012

A common enzyme that is easily detected in blood may predict how well patients with advanced kidney cancer will respond to a specific treatment, according to doctors at Duke Cancer Institute.

Optimal dose suggested for dasatinib in ovarian cancer

Nov 19, 2012

(HealthDay)—A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer, ...

Recommended for you

US OKs first-ever DNA alternative to Pap smear (Update 2)

5 hours ago

U.S. government health regulators have cleared a genetic test from Roche as a first-choice screening option for cervical cancer. It was a role previously reserved for the Pap smear, the decades-old mainstay of women's health.

New breast cancer imaging method promising

11 hours ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

12 hours ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

User comments